NCT04642937 2023-01-27
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
OX2 Therapeutics
Phase 1 Unknown
OX2 Therapeutics
The First Affiliated Hospital of Soochow University
TransThera Sciences (Nanjing), Inc.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Shenzhen Second People's Hospital